Document:

<PAGE>   1
                                                                    EXHIBIT 10.2

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

            AMENDMENT NO. 2 TO AMENDED AND RESTATED LICENSE AGREEMENT

         This Amendment No. 2 (the "Amendment"), dated as of March 29, 2001, is
by and between Rorer Pharmaceutical Products, Inc., a Delaware corporation
having it principal place of business at 3711 Kennett Pike, Suite 200,
Greenville, Delaware ("RPPI"), and Noven Pharmaceuticals, Inc., a Delaware
corporation having its principal place of business at 11960 S.W. 144th Street,
Miami, Florida ("Noven"), and amends the Amended and Restated License Agreement,
dated as of September 30, 1999 between an Affiliate of RPPI and Noven relating
to Estrogen, Progestin and Combination Products (the "Agreement"), a copy of
which is attached as EXHIBIT A hereto, as amended by Amendment to the Amended
and Restated License Agreement dated as of October 1, 1999, by and between RPR
and Noven ("Amendment No. 1"), a copy of which is attached as EXHIBIT B hereto.
All capitalized terms used in this Amendment without definition have the
meanings given to such terms in the Agreement.

                                    RECITALS

         WHEREAS, pursuant to the Agreement, Noven initially granted to Rhone
Poulenc Rorer Pharmaceuticals, Inc., an Affiliate of RPPI, among other things,
an exclusive license under Noven's Patent Rights and Noven's Technology to use,
sell or otherwise dispose of CombiPatch Product (as defined below) in the United
States and its territories and possessions (the "United States");

         WHEREAS, Rhone Poulenc Rorer Pharmaceuticals, Inc. assigned the
Agreement to RPPI pursuant to an Assignment and Assumption Agreement dated
September 30, 1999;

         WHEREAS, in the fourth quarter of 1999 the corporate parent of RPPI was
a party to a merger that created Aventis Pharma SA and RPPI desires to change
all references to it in the Agreement from "RPPI" to "Aventis";

         WHEREAS, RPPI and Noven wish to amend the Agreement to grant back from
RPR to Noven all rights granted under the Agreement with respect to the use,
sale or other disposal of CombiPatch Product in the United States;

         WHEREAS, RPPI and Noven wish to amend the Agreement to grant back from
RPPI to Noven all rights to use, sell or otherwise dispose of Progestin
Transdermal Drug Delivery Systems in the Territory, effectively terminating the
license granted by Noven to RPPI with respect to the Progestin Transdermal Drug
Delivery System, which was not developed by RPPI, such grant-back not to be
considered in any manner as a failure of RPPI to meet its obligations under the
Agreement, all on the terms and conditions described herein;

         WHEREAS, pursuant to Amendment No. 1, RPPI granted an exclusive
sublicense to Noven to use, sell and otherwise dispose of Licensed Products (as
defined in the Agreement) solely for use in the Contraceptive Field (as defined
in Amendment No. 1);

                                       1
<PAGE>   2
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

         WHEREAS, RPPI and Noven wish to modify the terms of Amendment No. 1 to
convert the exclusive sublicense granted therein to a grant-back, with only the
continuing obligations of Noven in favor of RPPI that are specifically set forth
herein;

         WHEREAS, Vivelle Ventures LLC, a Delaware limited liability company
("Vivelle") and RPPI desire to enter into a transaction pursuant to which, among
other things, RPPI will assign, transfer and sell to Vivelle all of RPPI's
right, title and interest in and to certain tangible and intangible assets
related to the CombiPatch Product in the United States;

         WHEREAS, Noven and Vivelle desire to enter into an agreement pursuant
to which Noven grants to Vivelle all rights granted back to Noven hereunder with
respect to the use, sale or other disposal of CombiPatch Product in the United
States; and

         WHEREAS, RPPI and Noven desire to enter into this Amendment to effect
the grant-back rights to Noven;

         NOW, THEREFORE, in consideration of the mutual covenants and
considerations set forth herein, the parties hereto, intending to be legally
bound, hereby agree as follows:

                                    AGREEMENT

         1. DEFINITIONS. Certain terms used herein and not defined have the
meanings given to such terms in the Agreement. As used herein, the following
terms shall have the following meanings:

                  "Affiliate" means, when used with respect to a Person, any
other Person directly or indirectly controlling, controlled by, or under common
control with the subject Person. For purposes of this Agreement, "control" means
the direct or indirect ownership of over 50% of the outstanding voting
securities of a Person, or to control the management decisions of such Person.

                  "Closing Date" has the meaning given in the Purchase Agreement
among Aventis, an Affiliate of Aventis and Vivelle.

                  "CombiPatch Product" means the transdermal estrogen/progestin
patch product which has been developed by Aventis, solely or jointly with Noven,
and/or their respective Affiliates, pursuant to the Agreement and is marketed
under the trademark CombiPatch(TM) in the United States.

                  "Contraceptive Field" means for the prevention of pregnancy.

                  "Person" means any corporation, partnership, joint venture,
other entity or natural person.

         2. AMENDED DEFINITIONS. All references in the Agreement to "RPR" and in
this Amendment to "RPPI" shall hereafter refer to and mean "Aventis". This
reference to "Aventis" is for convenience and does not represent any transfer or

                                       2
<PAGE>   3
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

assignment by RPPI under the Agreement to Aventis Pharma SA or any of its
subsidiaries. In addition, the following definitions in the Agreement are hereby
deleted in their entirety and are hereby replaced with the following:

                  "1.13 LICENSED PRODUCT(S). The term "Licensed Product" or
         "Licensed Products" shall mean individually and collectively any
         Estrogen Transdermal Drug Delivery System or any Combination
         Estrogen/Progestin Drug Delivery System. A Licensed Product relating to
         the Estrogen Transdermal Drug Delivery System shall be referred to as
         an "Estrogen Product" and a Licensed Product relating to the
         Combination Estrogen/Progestin Drug Delivery System shall be referred
         to as a "Combination Product."

                  "1.25 TERRITORY. The term "Territory" shall mean all the
         countries and territories worldwide as to any Combination Product other
         than CombiPatch Product; shall mean all the countries and territories
         worldwide except the United States, its territories and possessions as
         to the CombiPatch Product; and shall mean Japan as to the Estrogen
         Product."

And the following definition in the Agreement is hereby deleted in its entirety
with respect to Combination Products and is hereby replaced with the following
with respect to Combination Products:

                  "1.16 NOVEN'S PATENT RIGHTS. The term "Noven's Patent Rights"
         shall mean any and all patents, including but not limited to reissues,
         extensions and patents of addition, and patent applications,
         continuations, divisionals and continuations-in-part that are owned or
         controlled by Noven and the claims of which cover the Licensed
         Products. Noven's Patent Rights include, without limitation, the United
         States patents and patent applications listed in EXHIBIT C attached
         hereto and all corresponding foreign patents and patent applications."

         3. GRANT BACK OF RIGHTS RELATING TO COMBIPATCH PRODUCT. The exclusive
right and license granted by Noven to Aventis pursuant to Section 3.1 of the
Agreement to use, sell or otherwise dispose of Licensed Products is hereby
terminated with respect to the use, sale or other disposal of CombiPatch Product
as formulated as at the date hereof in the United States, its territories and
possessions. For the avoidance of doubt, the right to make modifications and/or
improvements to the CombiPatch Product and to develop, use, sell or otherwise
dispose of any such modifications and/or improvements in the Territory,
including, without limitation, the United States (in each case insofar as such
rights are granted pursuant to the Noven License Agreement) are not terminated
pursuant to the foregoing.

         4. GRANT BACK OF RIGHTS RELATING TO PROGESTIN PRODUCT.

                  (a) The license granted by Noven to Aventis in Section 3.1 of
the Agreement to use, sell or otherwise dispose of Progestin Transdermal Drug
Delivery Systems is hereby terminated.

                  (b) Section 1.21 of the Agreement (the definition of Progestin
Transdermal Drug Delivery System) shall be deleted in its entirety.

                                       3
<PAGE>   4
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                  (c) All other references in the Agreement to Progestin
Transdermal Drug Delivery System shall be deleted.

                  (d) It is understood that notwithstanding anything contained
in the Agreement to the contrary, neither Noven nor Aventis shall have any
obligation of any kind under the Agreement, financial or otherwise, with respect
to the development or commercialization of a Progestin Transdermal Drug Delivery
System. Furthermore, each of Noven and Aventis hereby waives any claim it may
have regarding the other party's performance of its obligations with respect to
Progestin Transdermal Drug Delivery Systems under the Agreement.

         5. GRANT BACK OF RIGHTS RELATING TO CONTRACEPTIVE FIELD. The Amendment
No. 1 relating to Licensed Products for use in the Contraceptive Field is hereby
terminated in its entirety and superseded by the following provisions:

                  (a) The license granted by Noven to Aventis in Section 3.1 of
the Agreement to use, sell or otherwise dispose of Licensed Products for use in
the Contraceptive Field is hereby terminated, and Noven shall have the right to
develop, use, sell or otherwise dispose of Licensed Products for use in the
Contraceptive Field.

                  (b) ***.

                  (c) It is understood that notwithstanding anything contained
in the Agreement to the contrary, neither Noven nor Aventis shall have any
obligation of any kind under the Agreement, financial or otherwise, with respect
to the development or commercialization of a Licensed Product for use in the
Contraceptive Field. Furthermore, each of Noven and Aventis hereby waives any
claim it may have regarding the other party's performance of its obligations
with respect to Licensed Products for use in the Contraceptive Field under the
Agreement.

         6. CONSIDERATION. In consideration for the grant back of rights from
Aventis to Noven under Section 3 above, Noven shall pay or cause to be paid to
Aventis, by wire transfer to an account specified in writing by Aventis, an
aggregate amount of Forty Million United States Dollars ($40,000,000) (the
"Consideration"), payable as follows:

                         AMOUNT                           DUE DATE
                         ------                           --------

                      $10,000,000                       June 1, 2001
                      $10,000,000                       September 4, 2001
                      $10,000,000                       December 3, 2001
                      $10,000,000                       March 1, 2002

         ***.

         7. NO LIABILITY FOR FUTURE PERFORMANCE.

                  (a) As of the Closing Date, Aventis and Noven agree that
Aventis shall have no liability to Noven for performance under the Agreement

                                       4
<PAGE>   5
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

with respect to the use, sale or other disposal of CombiPatch Product in the
United States, including, without limitation:

                           (i) payments for CombiPatch Product in the United
                  States pursuant to Section 4.2 of the Agreement;

                           (ii) payments for CombiPatch Product in the United
                  States pursuant to Section 4.4(a)(i) of the Agreement;

                           (iii) the transfer price established in Section
                  4.4(b)(B) of the Agreement;

                           (iv) liability for any minimum sales of CombiPatch
                  Product in the United States pursuant to Section 4.6;

                           (v) meeting any obligation to purchase from Noven up
                  to 90% of the previously forecasted quarterly requirements for
                  CombiPatch Product pursuant to the Supply Agreement to the
                  extent such forecasted amounts related to projected sales of
                  CombiPatch Product in the United States; and

                           (vi) reimbursement for any development or patent
                  costs and expenses, including maintenance costs.

                  (b) On the Closing Date Aventis and two of its Affiliates
intend to enter into a Sublicense Agreement (the "2001 Sublicense Agreement")
with Novartis Pharma AG ("Novartis") with respect to a sublicense under the
Agreement for rights related to Licensed Product worldwide, except Japan.
Aventis and Noven agree that following the execution of the 2001 Sublicense
Agreement, Novartis shall be solely responsible for certain obligations
identified on Schedule 2.2 to the 2001 Sublicense Agreement and those identified
in Section 3.2 of the 2001 Sublicense Agreement arising under the Agreement out
of the development, use, sale or other disposal of Licensed Product worldwide,
except Japan. Noven hereby acknowledges and agrees that after the Closing Date,
except as set forth in this Amendment, neither Aventis nor any of its Affiliates
shall have any financial or diligence obligations under the Agreement except for
those related to the development, use, sale or other disposal of Licensed
Product in Japan. Without limiting the foregoing, Noven agrees that neither
Aventis nor any of its Affiliates shall have any liability for any obligations
under the Agreement that arise under the activities performed (or not performed)
by Novartis under the sublicense granted to it, even if such obligations are not
assumed by Novartis under the 2001 Sublicense Agreement.

However, Aventis shall pay to Noven any remainder payments due under Section
4.4(c) of the Agreement as to all Licensed Product sold between January 1, 2001
and the Closing Date within sixty (60) days of the Closing Date.

         8. SCHEDULE OF ACCRUED LIABILITIES TO NOVEN. Notwithstanding the
foregoing Section 7 of this Amendment, all accrued liabilities to Noven listed
in the attached Schedule A shall be paid by Aventis to Noven in immediately
payable funds on the date indicated on Schedule A.

                                       5
<PAGE>   6
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

         9. SURVIVAL OF INDEMNIFICATION. Notwithstanding any provision of this
Amendment, nothing will affect the indemnification provisions of Sections 10.1
and 10.2 of the Agreement. Without limiting the foregoing sentence, Sections
10.1 and 10.2 of the Agreement shall remain in full force and effect as between
Noven and Aventis with respect to CombiPatch Product sold in the United States
on or prior to the Closing Date.

         10. AMENDMENT OF TERMINATION RIGHTS.

                  (a) Section 8.1(c) of the Agreement is hereby amended and
restated in its entirety as follows:

                          "(c) Upon expiration of this License Agreement
                  pursuant to this Article 8.1 in any country, Aventis shall
                  have the right to elect to renew this License Agreement for
                  successive five-year terms by giving Noven written notice of
                  its intention to do so prior to the end of any such term;
                  provided, however, that in the event of any such renewal the
                  parties will negotiate in good faith the fees provided for in
                  Articles 4.1 and 4.2(a) to take account of the expiration of
                  the applicable patents."

                  (b) With respect to Noven and Aventis, (i) the provisions of
Section 8.2(a) of the Agreement shall, as of the Closing Date, give Aventis the
right to terminate the Agreement only in Japan in the event Noven breaches its
obligations under the Agreement; (ii) the provisions of Section 8.2(b) of the
Agreement shall, as of the Closing Date, give each party hereto the right to
terminate the Agreement only in Japan in the event of any occurrence
contemplated by Section 8.2(b) with respect to the other party hereto; and (iii)
the provisions of Section 8.2(e) of the Agreement shall, as of the Closing Date,
give Aventis the right to terminate the Agreement only in Japan in the event of
any occurrence contemplated by Section 8.2(e).

                  (c) Section 8.2(d) of the Agreement is hereby amended and
restated in its entirety as follows:

                           "(d) (i) With respect to each Licensed Product, Noven
                  shall have the right to terminate this License Agreement in
                  Japan at any time upon thirty (30) days' notice if Aventis,
                  its Sublicensee, or an Aventis Affiliate that Aventis
                  controls, markets, sells or distributes any transdermal
                  product that is identical or substantially similar to such
                  Licensed Product, unless Aventis shall effect cessation of
                  such activity or divestiture of such Affiliate, or take action
                  towards such cessation or such divestiture within six (6)
                  months of the commencement of such activity or Aventis'
                  acquisition of such Affiliate. ***.

                                    (ii) Noven shall have the right to terminate
                  this License Agreement at any time upon thirty (30) days'
                  notice in any country of the Territory, except Japan, in which
                  Novartis, or any of its Affiliates (other than Vivelle) or
                  sublicensees, markets, sells or distributes any transdermal
                  product, except for a Licensed Product, that is identical or
                  substantially similar to any Licensed Product sublicensed to
                  Novartis Pharma AG ("Novartis") pursuant to the Sublicense

                                       6
<PAGE>   7
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                  Agreement dated September 30, 1999 between Aventis and
                  Novartis (the "Sublicense Agreement"); PROVIDED, HOWEVER, that
                  this right of termination does not apply (i) with respect to
                  the countries in the European Economic Area, (ii) ***.

                                    (iii) During the term of this Agreement, if
                  Novartis, or any of its Affiliates (other than Vivelle) or
                  sublicensees, markets, sells or distributes any transdermal
                  product, except for a Licensed Product, that is identical or
                  substantially similar to the Licensed Product sublicensed to
                  Novartis pursuant to the Sublicense Agreement in a country
                  within the European Economic Area, then Noven, with regard to
                  such country, shall have the right to convert the license
                  granted under Article 3 with respect to such Licensed Product
                  to a non-exclusive license; PROVIDED, HOWEVER, that this right
                  shall not apply: ***.

         11. EFFECTIVENESS OF THIS AMENDMENT. The parties acknowledge and agree
that this Amendment is being entered into in connection with other agreements
between Aventis, Noven and/or Novartis Pharma AG or Vivelle, including, but not
limited to, the Supply Agreement between Noven and Vivelle and the Purchase
Agreement among Aventis, an Aventis Affiliate and Vivelle. The parties further
acknowledge and agree that this Amendment shall be deemed to be effective on the
day prior to the closing contemplated by such other agreements, but that this
Amendment will not be effective unless and until all such other agreements,
including the Supply Agreement between Noven and Vivelle and those agreements
defined as "Related Agreements" in the Purchase Agreement, are effective.

         12. MISCELLANEOUS.

                  (a) The parties agree that as of the Closing Date,
         notwithstanding anything contained in the Agreement to the contrary,
         neither Noven nor Aventis shall have any obligation to the other of any
         kind under the Agreement, financial or otherwise, except for those
         obligations expressed in this Amendment, with respect to the
         development or commercialization of CombiPatch Product in the United
         States.

                  (b) Each party agrees to execute, acknowledge and deliver such
         further instruments, and to do all such other acts, as may be
         reasonably necessary or appropriate in order to carry out the purposes
         and intent of this Amendment.

                  (c) In the event of any conflict between the terms of this
         Amendment and the terms of the Agreement, the terms of this Amendment
         shall control.

                  (d) Except as expressly modified by this Amendment, the terms
         and provisions of the Agreement shall remain in full force and effect.

                                       7
<PAGE>   8
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

         IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 2
to be executed by their duly authorized representatives as of the date first
written above.

                           RORER PHARMACEUTICAL PRODUCTS, INC.

                           By:     /s/ Phillip R. Ridolfi
                               ------------------------------------------------
                                 Phillip R. Ridolfi
                                 President

                           NOVEN PHARMACEUTICALS, INC.

                           By:     /s/ Robert C. Strauss
                               ------------------------------------------------
                                 Robert C. Strauss
                                 President, Chief Executive Officer and
                                 Co-Chairman

                                       8<PAGE>   1
                                                                    EXHIBIT 10.3

                              SUBLICENSE AGREEMENT

                                      among

                      RORER PHARMACEUTICAL PRODUCTS, INC.,

                            RHONE-POULENC RORER INC.,

                      AVENTIS PHARMACEUTICALS PRODUCTS INC.

                 RHONE-POULENC RORER INTERNATIONAL HOLDINGS INC.

                                       and

                               NOVARTIS PHARMA AG

                                       and

                           NOVEN PHARMACEUTICALS, INC.

                                 MARCH 29, 2001

<PAGE>   2

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>

                                                                                                               PAGE
                                                                                                               ----

<S>                   <C>                                                                                        <C>
ARTICLE I             DEFINITIONS.................................................................................2

         1.1.         Definitions.................................................................................2
         1.2.         Product Formulated as of the Date Hereof....................................................5

ARTICLE II            SUBLICENSE GRANT............................................................................5

         2.1.         Sublicense to Sublicensed Noven Intellectual Property.......................................5
         2.2.         Assumption of Obligations...................................................................6
         2.3.         Retention of Rights.........................................................................6
         2.4.         Right to Sublicense.........................................................................6
         2.5.         ***.........................................................................................6
         2.6.         ***.........................................................................................7
         2.7.         ***.........................................................................................7

ARTICLE III           CONSIDERATION...............................................................................7

         3.1.         ***.........................................................................................7
         3.2.         Payment of Noven's Patent Costs.............................................................7

ARTICLE IV            RIGHT OF REFERENCE..........................................................................7

         4.1.         ***.........................................................................................7
         4.2.         ***.........................................................................................7
         4.3.         ***.........................................................................................7

ARTICLE V             TRADEMARKS AND DOMAIN NAMES.................................................................8

         5.1.         ***.........................................................................................8
         5.2.         ***.........................................................................................8
         5.3.         ***.........................................................................................8
         5.4.         ***.........................................................................................8
</TABLE>

                                       i

<PAGE>   3

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

<TABLE>
<CAPTION>

                                                                                                               PAGE
                                                                                                               ----

<S>                   <C>                                                                                        <C>
ARTICLE VI            INTELLECTUAL PROPERTY CLAIMS................................................................8

         6.1.         Infringement or Other Actions Regarding the Assigned Licensed Product Know-How..............8
         6.2.         Infringement or Other Actions Regarding Intellectual Property Rights........................8
         6.3.         ***.........................................................................................9
         6.4.         ***.........................................................................................9
         6.5.         Other Third Party Claims....................................................................9

ARTICLE VII           CONFIDENTIALITY AND NONCOMPETITION..........................................................9

         7.1.         Confidentiality; Press Releases.............................................................9
         7.2.         ***........................................................................................11
         7.3.         ***........................................................................................11
         7.4.         ***........................................................................................11
         7.5.         Noncompetition by Noven....................................................................11

ARTICLE VIII          INDEMNIFICATION............................................................................11

         8.1.         Indemnification............................................................................11

ARTICLE IX            TERM AND TERMINATION; REMEDIES.............................................................13

         9.1.         Term.......................................................................................13
         9.2.         Termination for Bankruptcy.................................................................13
         9.3.         Noven Termination Right....................................................................13
         9.4.         Remedies for Breach........................................................................14
         9.5.         Effect of Termination......................................................................15
         9.6.         ***........................................................................................15
         9.7.         Remedies Reasonable........................................................................15
         9.8.         No Penalties...............................................................................15
         9.9.         Force Majeure..............................................................................15

ARTICLE X             CERTAIN ADDITIONAL COVENANTS,
                      REPRESENTATIONS AND AGREEMENTS.............................................................16

         10.1.        ***........................................................................................16
         10.2.        ***........................................................................................16

</TABLE>

                                       ii
<PAGE>   4

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

<TABLE>
<CAPTION>

                                                                                                               PAGE
                                                                                                               ----

<S>                   <C>                                                                                        <C>
ARTICLE XI            MISCELLANEOUS..............................................................................16

         11.1.        Disputes...................................................................................16
         11.2.        Independent Contractors....................................................................16
         11.3.        Assignment.................................................................................16
         11.4.        Binding Effect; Benefit....................................................................17
         11.5.        Amendment..................................................................................17
         11.6.        No Waiver..................................................................................17
         11.7.        Notices....................................................................................17
         11.8.        Counterparts...............................................................................18
         11.9.        Interpretation.............................................................................18
         11.10.       Governing Law..............................................................................19
         11.11.       Severability...............................................................................19
         11.12.       Entire Agreement...........................................................................19
         11.13.       Further Assurances.........................................................................19
         11.14.       Inconsistency..............................................................................19

</TABLE>

                                      iii
<PAGE>   5

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                              SUBLICENSE AGREEMENT

THIS SUBLICENSE AGREEMENT (this "AGREEMENT"), dated as of March 29, 2001, is by
and among RORER PHARMACEUTICAL PRODUCTS, INC, a Delaware corporation with its
principal office at 3711 Kennett Pike, Suite 200, Greenville, Delaware U.S.A.
19807 (hereinafter referred to as "AVENTIS"), RHONE-POULENC RORER INC., a
Pennsylvania corporation with its principal office at Route 202-206,
Bridgewater, New Jersey, 08807 ("RPR"), AVENTIS PHARMACEUTICALS PRODUCTS INC., a
Delaware corporation with its principal office at Route 202-206, Bridgewater,
New Jersey , 08807 ("APPI"), Rhone-Poulenc Rorer International Holdings Inc., a
Delaware corporation with its principal office at 3711 Kennett Pike, Suite 200,
Greenville, Delaware U.S.A. 19807 ("RPRIH") and NOVARTIS PHARMA AG, a
corporation organized under the laws of Switzerland with its principal office at
Lichtstrasse 35, CH-4002 Basel, Switzerland ("NOVARTIS"), and NOVEN
PHARMACEUTICALS, INC., a Delaware corporation with its principal office at 11960
S.W. 144th Street, Miami, Florida 33186 ("NOVEN"). For purposes of this
Agreement, each of Aventis, RPR, APPI, RPRIH and Novartis are a "PARTY" to this
Agreement, and collectively Aventis, RPR, APPI, RPRIH and Novartis are the
"PARTIES" to this Agreement. Noven is a Party to this Agreement solely with
respect to the following applicable provisions of the Agreement: Section 2.1
(Sublicense to the Sublicensed Noven Intellectual Property); Section 2.2
(Assumption of Obligations); Section 2.3 (Retention of Rights); Section 2.4
(Right to Sublicense); Section 3.2 (Payment of Noven's Patent Costs); Sections
6.1, 6.2 and 6.5 (Infringement and Other Third Party Claims); Section 7.2(e)
(Noncompetition); Section 7.5 (Noncompetition by Noven); Article VIII
(Indemnification); Sections 9.1, 9.2, 9.3, 9.4, 9.5, 9.7, 9.8 and 9.9 (relating
generally to Term, Termination, Remedies and Penalties) and Article XI
(Miscellaneous).

                                    RECITALS

         WHEREAS, Rhone-Poulenc Rorer Pharmaceuticals, Inc. and Noven are
parties to an Amended and Restated License Agreement dated as of September 30,
1999, as amended by Amendment No. 2 thereto effective as of the day before the
date hereof (collectively, the "NOVEN LICENSE AGREEMENT") attached hereto as
EXHIBIT A, pursuant to which Noven granted Rhone-Poulenc Rorer Pharmaceuticals,
Inc. an exclusive right and license under Noven's Patent Rights and Noven's
Technology (each as defined in the Noven License Agreement) to develop, use,
sell or otherwise dispose of Licensed Products (as defined in the Noven License
Agreement);

         WHEREAS, Rhone-Poulenc Rorer Pharmaceuticals, Inc. assigned the Noven
License Agreement to Aventis pursuant to an Assignment and Assumption Agreement
dated September 30, 1999;

         WHEREAS, Novartis and Aventis have previously entered into a Sublicense
Agreement (the "EXISTING NOVARTIS PHARMA SUBLICENSE AGREEMENT") dated as of
September 30, 1999, pursuant to which Aventis granted to Novartis certain of its
rights related to "licensed product" in the "territory" (each as defined in the
Existing Novartis Pharma Sublicense Agreement); and

                                       1
<PAGE>   6
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

         WHEREAS, the Parties and Noven desire to enter into a transaction
pursuant to which, among other things, (a) Aventis will grant to Novartis an
exclusive sublicense to develop, use, sell or otherwise dispose of any and all
Licensed Product; (b) APPI and RPRIH, and RPR, will assign and transfer to
Novartis the Trademarks and the Domain Names, respectively, (c) Aventis and
Novartis will agree, effective as of the date hereof, to revise and replace
certain rights and obligations under the Existing Novartis Pharma Sublicense
Agreement, and (d) Novartis and Noven will agree to revise and replace certain
rights and obligations under the Noven License Agreement, all on the terms and
conditions contained in this Agreement;

         NOW, THEREFORE, in consideration of the mutual covenants and
considerations set forth herein, the Parties hereto, intending to be legally
bound, hereby agree as follows:

                                    ARTICLE I

                                   DEFINITIONS

         1.1. DEFINITIONS. As used herein, the following capitalized terms shall
have the following meanings:

         "AFFECTED PARTY" has the meaning set forth in Section 9.4 hereof.

         "AFFILIATE" means, when used with respect to a Person, any other Person
directly or indirectly controlling, controlled by, or under common control with
the subject Person. For purposes of this Agreement, "control" means the direct
or indirect ownership of over 50% of the outstanding voting securities of a
Person, or to control the management decisions of such Person.

         "AMENDMENT AGREEMENT" means Amendment No. 2 to the Noven License
Agreement between Aventis and Noven executed prior to the Closing Date and
effective as of the day before the Closing Date.

         ***.

         "AVENTIS INDEMNITEES" has the meaning set forth in Section 8.1(a)
hereof.

         "CLAIMS" has the meaning set forth in Section 8.1(a) hereof.

         "CLOSING DATE" has the meaning set forth in the Purchase Agreement.

         "COMBIPATCH PRODUCT" means the transdermal estrogen/progestin product
which has been developed by Noven, solely or jointly with Aventis or its
Affiliates, and is marketed and sold by Aventis and its Affiliates under the
trademark CombiPatchTM in the United States as of the Closing Date, and which,
without limiting the foregoing, is sold, assigned and transferred to Vivelle
under the Vivelle License Agreement and the Purchase Agreement.

         "COMPETING PRODUCT" means ***.

                                       2
<PAGE>   7
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

         "CONFIDENTIAL INFORMATION" means all proprietary data, know-how and
related information, including all regulatory approvals and related filings,
applications and data, the content of any unpublished patent applications,
operating methods and procedures, marketing, distribution and sales methods and
systems, sales figures and other business information and the Noven Confidential
Information disclosed to Aventis pursuant to the Noven License Agreement.

         "CONSIDERATION" has the meaning set forth in Section 3.1 hereof.

         "COURT" has the meaning set forth in Section 7.2(d) hereof.

         "DISCLOSING PARTY" has the meaning set forth in Section 7.1(a) hereof.

         ***.

         "ESTALIS(R)" has the meaning set forth in Section 5.3(a) hereof.

         "ESTALIS PRODUCT" means the product which is the Licensed Product as
defined in the Existing Novartis Pharma Sublicense Agreement.

         "FDA ACT" means the United States Federal Food, Drug and Cosmetic Act,
as amended, and the regulations promulgated thereunder, as amended from time to
time.

         "IND" means an Investigational New Drug Application as defined in the
FDA Act, or an equivalent application in another country or group of countries.

         "LICENSED PRODUCT" means any Combination Product (as defined in the
Noven License Agreement) to which Aventis has any rights in the Territory under
the Noven License Agreement as amended other than the Estalis Product,
including, without limitation, any improvements or modifications, or proposed
improvements or modifications, to the CombiPatch Product or the Estalis Product.

         "LOSSES" has the meaning set forth in Section 8.1(a) hereof.

         "NDA" means a New Drug Application as defined in the FDA Act, or an
equivalent application for Regulatory Approval in another country or group of
countries.

         "NOVARTIS INDEMNITEES" has the meaning set forth in Section 8.1(b)
hereof.

         "NOVEN INDEMNITEES" has the meaning set forth in Section 8.1(c) hereof.

         "OFFENDING PRODUCT" has the meaning set forth in Section 9.3(a).

         "ONGOING OBLIGATIONS" has the meaning set forth in Section 9.6 hereof.

         ***.

         "PERSON" means any corporation, partnership, joint venture, other
entity or natural person.

                                       3
<PAGE>   8
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

         "PURCHASE AGREEMENT" means the Purchase Agreement between Aventis, APPI
and Vivelle dated on the date hereof.

         "PURCHASER SUBLICENSE LETTER AGREEMENT" means the Letter Agreement
between, inter alia, Vivelle and Novartis dated March 29, 2001 pursuant to which
Novartis shall offer to sublicense to Vivelle all of its rights under this
Agreement in the United States on a product-by-product basis.

         "RECEIVING PARTY" has the meaning set forth in Section 7.1(a) hereof.

         "REGULATORY APPROVAL" means filing for and receipt of all governmental
and regulatory registrations and approvals (including, but not limited to,
approvals of all final labeling and pricing approvals of any Licensed Product)
required for the marketing and sale of any Licensed Product in the Territory
existing at the Closing Date.

         ***.

         "REGULATORY AUTHORITY" means the U.S. Food and Drug Administration, and
any equivalent regulatory agency in any country in the Territory.

         "RELATED AGREEMENTS" means the Purchase Agreement, the Amendment
Agreement, the Purchaser Sublicense Letter Agreement and the Vivelle License
Agreement.

         "SUBLICENSED NOVEN INTELLECTUAL PROPERTY" means Noven's Patent Rights
and Noven's Technology (as each such term is defined in the Noven License
Agreement) which are licensed to Aventis pursuant to the Noven License
Agreement. Noven's Patent Rights at the date hereof include, without limitation,
those patents and patent applications listed in SCHEDULE A attached hereto.

         "TERRITORY" means worldwide, except Japan.

         ***.

         ***.

         ***.

         "UNITED STATES" means the United States, its territories and
possessions.

         "VIVELLE" means Vivelle Ventures LLC, a Delaware limited liability
company and joint venture owned by Noven and Novartis Pharmaceuticals
Corporation, which is the Purchaser under the Purchase Agreement.

         "VIVELLE LICENSE AGREEMENT" means the License Agreement between Noven
and Vivelle dated on the Closing Date.

         ***.

                                       4
<PAGE>   9
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

         1.2. PRODUCT FORMULATED AS OF THE DATE HEREOF. Wherever, in this
Agreement, reference is made to the Estalis Product or the CombiPatch Product
"formulated as of the date hereof", such expression may include different dosage
strengths of the Estalis Product or the CombiPatch Product, as the case may be.
To be considered Estalis Product or the CombiPatch Product "formulated as of the
date hereof", ***.

                                   ARTICLE II

                                SUBLICENSE GRANT

         2.1. SUBLICENSE TO SUBLICENSED NOVEN INTELLECTUAL PROPERTY.

                  (a) Subject to the terms and conditions of this Agreement,
with effect from the Closing Date, Aventis hereby grants to Novartis, and
Novartis hereby accepts, during the term of this Agreement, an exclusive (even
as to Aventis and its Affiliates) sublicense to all rights and benefits of
Aventis and its Affiliates arising out of or under the Noven License Agreement
in the Territory. For the avoidance of doubt, (i) the Parties acknowledge that
the Amendment Agreement is effective in all respects prior to the grant of the
sublicense granted hereunder; (ii) the foregoing sublicense includes, without
limitation, the right to make modifications and/or improvements to the
CombiPatch Product and to develop, use, sell or otherwise dispose of any such
modifications and/or improvements in the Territory, including, without
limitation, the United States (in each case insofar as such rights are granted
pursuant to the Noven License Agreement as modified hereby), but shall not
include the right to use, sell or otherwise dispose of the CombiPatch Product in
the United States; and (iii) the foregoing sublicense shall include any of
Noven's Patent Rights or Noven's Technology (each as defined in the Noven
License Agreement) which relate to any improvement or proposed improvement to
the CombiPatch Product or the Estalis Product including, without limitation, the
improvements or proposed improvements described in SCHEDULE 2.1(A).

                  (b) Novartis acknowledges and agrees that the sublicense
granted pursuant to Section 2.1(a) is and shall be subordinate to, and subject
to the terms and conditions of, the license granted to Aventis by Noven pursuant
to the Noven License Agreement except as otherwise provided herein. Without
limiting the foregoing, the Parties acknowledge that, pursuant to the Amendment
Agreement and this Agreement; (i) Aventis has no right to terminate the rights
under the Noven License Agreement in the Territory or the rights to the
sublicense granted hereunder, and (ii) Noven has no right to terminate the Noven
License Agreement in the Territory, but Noven shall, after the Closing Date,
have the right to terminate the sublicense granted hereunder, in which event
such termination shall operate as a termination of the Noven License Agreement
in the Territory by Noven under Sections 8.2(a), (b) or (d) of the Noven License
Agreement, and the Parties further agree that Novartis may enforce against Noven
directly the rights granted hereunder to Novartis pursuant to the Noven License
Agreement as amended hereby.

                  (c) Noven hereby consents to the grant under this Section 2.1
of the sublicense from Aventis to Novartis in consideration for Novartis

                                       5
<PAGE>   10

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

assuming the obligations referenced in Section 2.2 and providing Noven a direct
means of enforcing such obligations against Novartis, in Articles VIII and IX.

         2.2. ASSUMPTION OF OBLIGATIONS. As between Novartis, its Affiliates and
sublicensees on the one hand and Aventis, its Affiliates and sublicensees on the
other hand, Novartis will be solely responsible for, and hereby assumes,
following the Closing Date, those obligations under the Noven License Agreement
with respect to the development, use, sale or other disposal of Licensed Product
in the Territory, which are set forth in SCHEDULE 2.2 attached hereto; PROVIDED,
HOWEVER, that, (a) in each case, Novartis shall be responsible, and hereby
assumes, such obligations only to the extent that such obligations relate
directly to the development, use, sale or other disposal of Licensed Product in
the Territory, and only to the extent that they have not been modified herein;
(b) Novartis, its Affiliates and sublicensees, shall not be bound by any
Development Plan agreed between Noven and Aventis; and (c) Novartis, its
Affiliates and sublicensees, shall not be bound by the provisions of the Supply
Agreement which is incorporated into the Noven License Agreement. The Parties
agree that, pursuant to the Amendment Agreement, Noven has relieved Aventis, its
Affiliates and sublicensees from any financial and diligence obligations under
the Noven License Agreement with respect to the development, use, sale or other
disposal of Licensed Product in the Territory that are not assumed by Novartis
hereunder. Novartis, its Affiliates and sublicensees, will negotiate, agree and
enter into separate arrangements with Noven regarding their development
obligations under the Noven License Agreement. Supply of any Licensed Product to
Novartis, its Affiliates and sublicensees, shall be the subject of separate
arrangements with Noven. With effect from not later than the Closing Date,
Aventis hereby releases Noven from the obligations of Noven set forth in Article
5.4 of the Noven License Agreement. Further, Aventis undertakes that,
notwithstanding any failure by Aventis to renew the Supply Agreement which is
incorporated in the Noven License Agreement, the term of the Lease Agreement
with respect to the Facility (as defined in the Noven License Agreement) shall
not expire, and shall be automatically renewed on the same terms, for the term
of this Agreement. Noven hereby consents to the foregoing provisions, and agrees
to use commercially reasonable efforts to co-operate with Novartis, its
Affiliates and sublicensees in the development of Licensed Products.

         2.3. RETENTION OF RIGHTS. Nothing in this Agreement as between Aventis
and Noven shall impair or limit the rights of Aventis under the Noven License
Agreement outside the Territory.

         2.4. RIGHT TO SUBLICENSE. The Parties agree that this Agreement grants
to Novartis no right to grant any sublicense under the sublicense granted to
Novartis pursuant to Section 2.1 hereof without the consent of Noven as required
under Article 3.1(d) of the Noven License Agreement; PROVIDED, HOWEVER, that
Novartis shall have the right to grant further sublicenses under the sublicense
granted to Novartis pursuant to Section 2.1 hereof to Vivelle (and Persons
acting on behalf of Vivelle) without obtaining prior approval from Noven.
Affiliates, agents, distributors, wholesalers and other independent resellers
shall not be considered sublicensees hereunder. Noven hereby consents to the
foregoing provision.

         2.5. ***.

                                       6
<PAGE>   11
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

         2.6. ***.

         2.7. ***.

                                   ARTICLE III

                                  CONSIDERATION

         3.1. ***.

         3.2. PAYMENT OF NOVEN'S PATENT COSTS. Following the Closing Date
Novartis shall assume Aventis' obligation, set forth in Articles 6.1 and 6.2 of
the Noven License Agreement, to pay patent filing fees, costs and expenses
incurred on a country by country basis in the Territory with respect to any such
Licensed Product; PROVIDED, HOWEVER, that Novartis shall not be obliged to pay
any patent filing fees, costs or expenses incurred in any country where neither
Novartis nor Noven expects a Licensed Product covered by the claims of the
applicable patent to be marketed. The Parties and Noven agree that Novartis will
be entitled to the same offset rights set forth in Articles 6.1 and 6.2 of the
Noven License Agreement as would otherwise be available to Aventis under such
articles. Upon the first sale of a Licensed Product by Novartis or any of its
Affiliates or sublicensees in a country in the Territory, Novartis' obligation
under this Section 3.2 will be relieved for that country. On and after the
Closing Date, and to the extent duplicative, this Section 3.2 shall supersede
the obligation of Novartis set forth in Section 3.5 of the Existing Novartis
Pharma Sublicense Agreement for all such patent expenses incurred after the
Closing Date. Noven shall cooperate with Novartis in connection with Novartis'
obligations under this Section 3.2, by, but not limited to, providing the
necessary information to enable Novartis to come to an informed decision whether
to pay expenses and providing an annual budget of costs which shall be discussed
promptly should it be significantly exceeded. Pursuant to the Amendment
Agreement, Noven has relieved Aventis, its Affiliates and sublicensees of all
obligations set forth in Articles 6.1 and 6.2 of the Noven License Agreement in
the Territory not assumed by Novartis hereunder. Noven hereby consents to the
foregoing provisions.

                                   ARTICLE IV

                               RIGHT OF REFERENCE

         4.1. ***.

         4.2. ***.

         4.3. ***.

                                       7
<PAGE>   12
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                                    ARTICLE V

                           TRADEMARKS AND DOMAIN NAMES

         5.1. ***.

         5.2. ***.

         5.3. ***.

         5.4. ***.

                                   ARTICLE VI

                          INTELLECTUAL PROPERTY CLAIMS

         6.1. INFRINGEMENT OR OTHER ACTIONS REGARDING THE ASSIGNED LICENSED
PRODUCT KNOW-HOW.

                  (a) If any Party shall become aware of any infringement or
threatened infringement of the Assigned Licensed Product Know-How or any unfair
competition, disparagement or other tortious act by any third party in relation
to the Assigned Licensed Product Know-How, then the Party having such knowledge
shall give prompt notice thereof to the other Party.

                  (b) Novartis, its Affiliates and sublicensees, shall have the
right to take such action as it deems appropriate to protect and enforce the
Assigned Licensed Product Know-How in the Territory, including but not limited
to, bringing an action, suit or other appropriate proceeding to prevent or
eliminate the infringement of such Assigned Licensed Product Know-How, or the
unfair competition, disparagement or other tortious act by any third party in
relation to the Assigned Licensed Product Know-How in the Territory. Aventis and
Noven each agree to cooperate with Novartis in any reasonable manner requested
by Novartis in any such action, suit or proceeding, at the expense of Novartis,
its Affiliates or sublicensees, as appropriate, including, without limitation,
joining as a party to such action, suit or proceeding, if necessary to maintain
standing.

                  (c) All amounts awarded as damages, profits or otherwise in
connection with any action taken by Novartis, its Affiliates or licensees, shall
be ***. If Novartis, its Affiliates and licensees, elect not to take any action
of the nature specified in Section 6.1(b), Novartis shall give Aventis notice of
such decision, and Aventis thereafter shall have the right to take any action of
the nature specified in Section 6.1(b) with respect to the use of the Assigned
Licensed Product Know-How in the Territory. In such event, all amounts awarded
as damages, profits or otherwise in connection with any action taken by Aventis
shall be ***.

         6.2. INFRINGEMENT OR OTHER ACTIONS REGARDING INTELLECTUAL PROPERTY
RIGHTS. (a) If any Party becomes aware of any infringement or threatened
infringement of (i) the Sublicensed Noven Intellectual Property or (ii) any

                                       8
<PAGE>   13

other intellectual property rights of the parties to the Noven License Agreement
used in the development, manufacture or marketing of Licensed Product,
(including, without limitation, by the filing of any certification in the United
States claiming that any such intellectual property rights are invalid or will
not be infringed by the manufacture, use or sale of a product by a third party)
such Party shall provide notice to all interested parties in accordance with
Article 6.4 of the Noven License Agreement, and comply with the provisions of
Article 6.4 of the Noven License Agreement with respect to the determination of
whether to prosecute the alleged infringement.

         (b) In the event Aventis is entitled to prosecute an infringement
action pursuant to Article 6.4 of the Noven License Agreement, Novartis hereby
assumes all such rights, and related obligations, after the Closing Date;
PROVIDED, HOWEVER, that (i) Aventis shall cooperate with and assist Novartis,
its Affiliates and sublicensees, in good faith with respect thereto; and (ii) in
the event Novartis, its Affiliates or sublicensees, brings any such action,
Noven shall, at the request of Novartis, provide Novartis, its Affiliates or
sublicensees, with reasonable assistance at the expense of Novartis, its
Affiliates or sublicensees, as appropriate, in accordance with Article 6.4 of
the Noven License Agreement.

         (c) ***.

         6.3. ***.

         6.4. ***.

         6.5. OTHER THIRD PARTY CLAIMS. If either Aventis or Noven becomes aware
of any action, suit or proceeding or threat of action, suit or proceeding, by a
third party alleging that the manufacture, use, import or sale of Licensed
Product in the Territory infringes or violates any other intellectual property
right of any third party, Aventis or Noven, as appropriate, shall promptly
notify Novartis of the same.

                                   ARTICLE VII

                       CONFIDENTIALITY AND NONCOMPETITION

         7.1. CONFIDENTIALITY; PRESS RELEASES.

                  (a) Pursuant to the terms hereof, from time to time during the
term of this Agreement, each of Novartis and Aventis and/or their respective
Affiliates and sublicensees (in such capacity, the "Disclosing Party") have
disclosed and will be disclosing to the other Party and/or its Affiliates (in
such capacity, the "Receiving Party") certain Confidential Information of the
Disclosing Party. The Receiving Party shall make no use of such Confidential
Information except in the exercise of its rights and performance of its
obligations set forth in this Agreement and the Related Agreements. The
Receiving Party shall use the same efforts to keep secret, and prevent the
disclosure to third parties of, Confidential Information of the Disclosing Party
as it would use with respect to its own Confidential Information. Confidential

                                       9
<PAGE>   14

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

Information disclosed by the Disclosing Party shall remain the sole and absolute
property of the Disclosing Party, subject to the rights granted in this
Agreement and the transactions contemplated herein. The above restrictions on
the use and disclosure of Confidential Information shall not apply to any
information which: (i) is already known to the Receiving Party at the time of
disclosure by the Disclosing Party, as demonstrated by competent proof; (ii) is
or becomes generally available to the public other than through any act or
omission of the Receiving Party in breach of this Agreement; (iii) is acquired
by the Receiving Party from a third party who is not, directly or indirectly,
under an obligation of confidentiality to the Disclosing Party with respect to
same; or (iv) is developed independently by the Receiving Party without use,
direct or indirect, of information that is required to be held confidential
hereunder.

                  In the event the Receiving Party is required: (i) by law, rule
or regulation to disclose Confidential Information of the Disclosing Party to
regulatory authorities to obtain and maintain regulatory approval for any
Licensed Product; (ii) to disclose Confidential Information of the Disclosing
Party to respond to a regulatory or governmental inquiry concerning any Licensed
Product; or (iii) to disclose Confidential Information of the Disclosing Party
in a judicial, administrative or arbitration proceeding to enforce such Party's
rights under this Agreement, it may do so only if it: (A) provides the
Disclosing Party with as much advance written notice as possible of the required
disclosure; (B) cooperates with the Disclosing Party in any attempt to prevent
or limit the disclosure; and (C) limits disclosure, if any, to the specific
purpose at issue.

                  (b) Notwithstanding the provisions of this Section 7.1, but
still subject to compliance with the terms of the Noven License Agreement,
Novartis, its Affiliates and sublicensees, shall be permitted to disclose to
their respective distributors, wholesalers and other direct customers such
Confidential Information relating to Licensed Product or improvements thereto as
Novartis, its Affiliates and sublicensees, shall reasonably determine to be
necessary or useful in order to effectively market and distribute any Licensed
Product; provided that such entities undertake substantially the same
confidentiality obligation as Novartis has with respect to Aventis' Confidential
Information.

                  (c) ***

                  (d) Except as may be required by applicable laws, rules or
regulations, no Party will originate any publicity, press or news release, or
other public announcement, written or oral, whether to the public press or
otherwise, relating to this Agreement or the Related Agreements, the
transactions contemplated hereby or thereby, or to the existence of an
arrangement between the Parties, without the prior written approval of the other
Party. In the event disclosure of this Agreement or any of the Related
Agreements, any of the terms and conditions of this Agreement or such Related
Agreements, or any of the transactions contemplated by this Agreement or such
Related Agreements, is required by applicable law, rules or regulations, then
the Party required to so disclose such information shall, to the extent
possible, provide to the other Party for its prior approval (such approval not
to be unreasonably withheld or delayed) a written copy of such public
announcement. When practicable, the disclosing Party will provide such copy to
the other Party at least five (5) business days prior to disclosure.

                                       10
<PAGE>   15
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                  (e) Neither Party shall use the name of the other for
marketing, advertising or promotional claims without the prior written consent
of the other Party.

         7.2. ***.

         7.3. ***:

         7.4. ***.

         7.5. NONCOMPETITION BY NOVEN. (a) Noven covenants that for a period
beginning on the date hereof and ending ***, neither it nor any of its
Affiliates or sublicensees shall market, sell or distribute (or agree with any
third party to do any of the foregoing) any Competing Product in the Territory,
other than the Estalis Product, the CombiPatch Product and Licensed Product(s).
Notwithstanding the foregoing, with respect to the marketing, sale or
distribution of any Competing Product in the Territory solely to the extent that
the marketing, sale or distribution of such Competing Product by Noven (or its
Affiliates or sublicensees) is the result of Noven (or its Affiliates or
sublicensees) having acquired the Competing Product from the acquisition of, or
merger with another Person who at the time of acquisition possessed such
Competing Product and/or was marketing, selling and/or distributing it in the
Territory, Noven, its Affiliate or sublicensee shall ***.

         (b) Noven recognizes that the territorial, time and scope limitations
set forth in this Section 7.5 are reasonable and are required for the protection
of Novartis, its Affiliates and sublicensees. Further, Noven specifically
recognizes that any breach by it of this Section 7.5 may cause irreparable
injury to the Novartis, its Affiliates and sublicensees (including, without
limitation, Vivelle) and that actual damages may be difficult to ascertain, and,
in any event, may be inadequate. Accordingly (and without limiting the
availability of legal or equitable, including injunctive, remedies under any
other provisions of this Agreement), Noven agrees that in the event of any such
breach, notwithstanding the provisions of Section 11.1, Novartis shall be
entitled to seek, by way of private litigation in the first instance, injunctive
relief and such other legal and equitable remedies as may be available.

                                  ARTICLE VIII

                                 INDEMNIFICATION

         8.1. INDEMNIFICATION. In order to distribute among themselves the
responsibility for claims arising out of this Agreement, and except as otherwise
specifically provided for herein, the Parties agree as follows:

                  (a) ***.

                  (b) ***.

                  (c) Novartis shall defend, indemnify and hold Noven, its
Affiliates, and each of their respective officers, directors, agents, employees
and shareholders (collectively, "NOVEN INDEMNITEES") harmless, from and against,

                                       11
<PAGE>   16
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

any and all Losses, which the Noven Indemnitees may incur or suffer, and all
Claims, with which any of them may be faced arising out of: (i) any material
inaccuracy in or material breach of any representation and warranty made by
Novartis in this Agreement; (ii) any material breach by Novartis or any of its
Affiliates or sublicensees, or material failure by any of them to comply with,
any covenants or obligations of Novartis pursuant to this Agreement; (iii) the
enforcement by the Noven Indemnitees of their rights under this Section 8.1(c);
(iv) any gross negligence or willful misconduct by Novartis or its Affiliates in
Novartis' performance pursuant to this Agreement; and (v) Novartis' material
violation of any applicable law or regulation; provided, however, that Novartis
shall not be liable hereunder to the extent such Losses arise from willful
misconduct or gross negligence of the Noven Indemnitees.

                  (d) Noven shall defend, indemnify and hold the Novartis
Indemnitees harmless, from and against, any and all Losses, which the Novartis
Indemnitees may incur or suffer, and all Claims with which any of them may be
faced arising out of: (i) any material inaccuracy in or material breach of any
representation and warranty made by Noven in the Noven License Agreement; (ii)
any material breach by Noven or any of its Affiliates or sublicensees, or
material failure by any of them to comply with, any covenants or obligations of
Noven pursuant to this Agreement or the Noven License Agreement; (iii) the
enforcement by the Novartis Indemnitees of their rights under this Section
8.1(d); (iv) any gross negligence or willful misconduct by Noven or its
Affiliates in Noven's performance pursuant to this Agreement or the Noven
License Agreement; and (v) Noven's material violation of any applicable law or
regulation; provided, however, that Noven shall not be liable hereunder to the
extent such Losses arise from willful misconduct or gross negligence of the
Novartis Indemnitees.

                  (e) If any Claim arises as to which a right of indemnification
provided in this Article VIII applies, the Person seeking indemnification (the
"indemnified party"), shall promptly notify the Party obligated under this
Article VIII to indemnify the indemnified party (the "indemnifying party")
thereof in writing, and allow the indemnifying party and its insurers the
opportunity to assume direction and control of the defense against such Claim,
at its sole expense, including, without limitation, the settlement thereof at
the sole option of the indemnifying party or its insurers; PROVIDED, HOWEVER,
that the indemnifying party may not enter into any compromise or settlement
without the prior written consent of the indemnified party unless such
compromise or settlement includes as an unconditional term thereof the giving by
each plaintiff or claimant to the indemnified party of a release from all
liability in respect of such claim and only if such compromise or settlement
does not include any admission of legal wrongdoing on the part of the
indemnified party. The indemnified party shall fully cooperate with the
indemnifying party and its insurer in the disposition of any such matter and the
indemnified party will have the right and option to participate in (but not
control) the defense of any Claim as to which this Article VIII applies, with
separate counsel at its election and cost. If the indemnifying party fails or
declines to assume the defense of any such Claim within thirty (30) days after
notice thereof, the indemnified party may assume the defense thereof for the
account and at the risk of the indemnifying party. The indemnifying party shall
pay promptly to the indemnified party any Losses to which the indemnity under
this Article VIII applies, as incurred.

                                       12
<PAGE>   17
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                                   ARTICLE IX

                         TERM AND TERMINATION; REMEDIES

         9.1. TERM. The term of this Agreement shall commence on the Closing
Date and, with respect to the sublicense granted pursuant to Section 2.1 shall
expire, unless sooner terminated as set forth herein, upon the expiration or
termination of the licenses granted to Aventis by Noven under the Noven License
Agreement. For purposes of this Section 9.1: (a) the licenses granted to Aventis
under the Noven License Agreement shall be deemed to include any licenses
obtained by Aventis pursuant to Article 8.3(b) of the Noven License Agreement;
and (b) Novartis shall have the benefit of, and the right to exercise, the
rights and options granted to Aventis pursuant to Article 8.1(c) of the Noven
License Agreement. Commencing on the first to expire of any patent in the United
States included under Noven's Patent Rights (as defined in the Noven License
Agreement), Novartis shall have the right, exercisable by notice in writing to
Noven on a Licensed Product-by-Licensed Product basis upon the launch of any
product on to the market in the United States which is "AB rated" to such
Licensed Product, to require Noven to negotiate in good faith the fees provided
for in any arrangement for supply of any Licensed Product to Novartis, its
Affiliates or sublicensees in the United States.

         9.2. TERMINATION FOR BANKRUPTCY. Any of Noven, Novartis or Aventis may
terminate this Agreement with immediate effect in the event that any proceeding
under a bankruptcy, liquidation or similar statute, or any insolvency,
receivership or dissolution proceeding is filed against the other Party, and
such proceeding is not dismissed within sixty (60) days after the filing
thereof.

         9.3. NOVEN TERMINATION RIGHT. (a) With respect to each Licensed
Product, and for a period beginning on the date hereof and ending ***, Noven
shall have the right to terminate this Agreement at any time upon thirty (30)
days' notice in any country of the Territory in which Novartis, its sublicensee,
or a Novartis Affiliate markets, sells or distributes any transdermal product
that is identical or substantially similar to such Licensed Product ("OFFENDING
PRODUCT"), unless Novartis shall effect cessation of such activity or
divestiture of such Affiliate, or take action towards such cessation or such
divestiture within 6 months of the commencement of such activity or Novartis'
acquisition of such Affiliate; PROVIDED, HOWEVER, that this right of termination
does not apply (i) with respect to the countries in the European Economic Area,
***.

         (b) With respect to each Licensed Product, and for a period beginning
on the date hereof and ending ***, if Novartis or any Novartis Affiliate or
sublicensee markets, sells or distributes any Offending Product in a country
within the European Economic Area, then Noven, with regard to such country,
shall have the right to convert the license granted under Article 3 of the Noven
License Agreement with respect to such Licensed Product to a non-exclusive
license; PROVIDED, HOWEVER, that this right shall not apply: (i) if Novartis
shall effect cessation of such activity or divestiture of such Affiliate or take
action towards such cessation or such divestiture within six months of the
commencement of such activity or Novartis' acquisition of such Affiliate; ***.

                                       13
<PAGE>   18
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

         (c) Notwithstanding Sections 9.3(a) and (b) above, with respect to the
marketing, sale or distribution of any transdermal product that is identical or
substantially similar to a Licensed Product in the Territory solely to the
extent that the marketing, sale or distribution of such product by Novartis (or
its Affiliates or sublicensees) is the result of Novartis (or its Affiliates or
sublicensees) having acquired the products from the acquisition of, or merger
with another Person who at the time of acquisition possessed such products
and/or was marketing, selling and/or distributing them in the Territory,
Novartis, its Affiliate or sublicensee may, instead of ceasing such activity or
divesting such product or Person, elect to pay to Noven reasonable compensation
agreed by the parties in good faith with respect thereto at the time of such
acquisition or merger, in which event, Noven shall have no right to terminate
this Agreement with respect to such Licensed Product or convert the license
granted under Article 3 of the Noven License Agreement with respect to such
Licensed Product to a non-exclusive license.

         (d) Novartis recognizes that the territorial, time and scope
limitations set forth in this Section 9.3 are reasonable and are required for
the protection of Noven, its Affiliates and sublicensees.

         (e) If Noven should terminate this Agreement against Novartis with
respect to any Licensed Product under this Section 9.3, it will have the rights
upon termination set forth in Section 8.3(a) of the Noven License Agreement with
respect to such Licensed Product.

         9.4. REMEDIES FOR BREACH. If either of Novartis or Aventis, RPR, RPRIH
or APPI commits a material breach of this Agreement, or materially defaults in
the performance or observance of any provision of this Agreement (including the
obligations assumed by Novartis under Section 2.2), and (i) such Party fails,
within sixty (60) days after receipt of notice of the material breach from the
Party affected by the breach or default (the "AFFECTED PARTY"), to remedy such
breach or default or to have agreed to a plan for remedy of such breach or
default and (ii) the Parties shall have exhausted the dispute resolution
procedures provided in Section 11.1 without resolving their dispute regarding
the material breach; PROVIDED that the time periods contemplated by the
foregoing clauses (i) and (ii) may run concurrently and need not be sequential,
the Affected Party shall have the following rights:

                  (a) REMEDIES FOR NOVARTIS.

                           (i) Upon the breach of this Agreement by Aventis,
         RPR, RPRIH or APPI under this Section 9.4, Novartis shall then have the
         right to terminate this Agreement, exercisable by delivering written
         notice thereof to Aventis, and/or to pursue any and all remedies
         available to it at law or in equity including, without limitation, the
         right to seek to recover from Aventis any and all damages and losses of
         any nature whatsoever (but excluding consequential damages, lost
         profits and punitive damages).

                           (ii) Without limiting any other provision of this
         Agreement, Noven acknowledges that the rights and benefits granted to
         Novartis pursuant to this Agreement include all rights of Aventis to
         terminate the Noven License Agreement in the Territory and all rights
         and benefits of Aventis upon any such termination in the Territory
         pursuant to the Noven License Agreement.

                                       14
<PAGE>   19

                  (b) REMEDIES FOR AVENTIS. ***.

                  (c) REMEDIES FOR NOVEN. Upon the breach by Novartis under this
Section 9.4 of any obligation owed by Novartis to Noven under this Agreement,
and subject to compliance by Noven with the provisions of this Section 9.4,
Noven shall have the right to pursue any and all remedies available to it at law
or in equity including without limitation the right to seek to recover from
Novartis any and all damages and losses of any nature whatsoever (but excluding
consequential damages, lost profits and punitive damages) and the right to
terminate this Agreement against Novartis. If Noven should terminate this
Agreement against Novartis under this Section 9.4(c), it will have the rights
upon termination set forth in Section 8.3(a) of the Noven License Agreement.

         9.5. EFFECT OF TERMINATION. Rights and obligations set forth in
Sections 7.1 (Confidentiality; Press Releases), 8.1 (Indemnification) and
Articles VI (Intellectual Property Claims) and XI (Miscellaneous) shall survive
the termination of this Agreement and/or the termination of the Ongoing
Obligations, and otherwise, except as set forth in this Section 9.5, this
Agreement shall become void and have no effect; PROVIDED, HOWEVER, that any
termination of this Agreement will have no impact on the assignments pursuant to
Sections 2.6, 4.1 or 5.1 hereof, and that any termination of this Agreement by
Novartis will have no impact on the sublicense granted to Novartis pursuant to
Section 2.1 hereof or pursuant to Section 2.1 of the Existing Novartis Pharma
Sublicense Agreement. Noven hereby consents to the foregoing proviso. Nothing in
this Section 9.5 shall relieve any Party to this Agreement of any liability for
a breach of any provision of this Agreement.

         9.6. ***.

         9.7. REMEDIES REASONABLE. The Parties expressly acknowledge that the
remedy provisions contained in this Article IX are reasonable, considering the
intended nature and scope of this Agreement.

         9.8. NO PENALTIES. Without limiting the indemnification rights set
forth in Article VIII hereof, if either Party terminates this Agreement in
accordance with the terms herein, the terminating Party shall owe no statutory
termination penalty or indemnity or other similar payment that might otherwise
be due under local law to the terminated Party on account of such termination.

         9.9. FORCE MAJEURE. The obligations of the Parties under this Agreement
shall be subject to any delays or non-performance caused by: acts of God,
earthquakes, fires or floods; explosions, sabotage, riots or accidents;
regulatory, governmental or military action or inaction; strikes, lockouts or
labor trouble; perils of the sea; failure or delay in performance by third
parties, including suppliers and service providers; or any other cause beyond
the reasonable control of either Party. The Party which is not performing its
obligations under this Agreement as a result of any such event of force majeure
will promptly notify the other Party thereof and shall use commercially
reasonable efforts to resume compliance with this Agreement as soon as possible.

                                       15
<PAGE>   20
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                                    ARTICLE X

                          CERTAIN ADDITIONAL COVENANTS,

                         REPRESENTATIONS AND AGREEMENTS

         10.1. ***.

         10.2. ***.

                                   ARTICLE XI

                                  MISCELLANEOUS

         11.1. DISPUTES. Except as set forth in Sections 7.3, 7.4 and 7.5(b) and
notwithstanding Article XI of the Noven License Agreement, in the event of any
controversy or claim arising out of, relating to or in connection with any
provision of this Agreement or the Noven License Agreement, or the rights or
obligations of the Parties hereunder or thereunder, the Parties shall try to
settle their differences amicably between themselves. Any Party may initiate
such informal dispute resolution by sending written notice of the dispute to any
other Party, and within ten (10) days after such notice appropriate
representatives of the relevant Parties shall meet for attempted resolution by
good faith negotiations. If such representatives are unable to resolve promptly
such disputed matter, it shall be referred to the Chief Executive Officer of
Novartis Pharma AG the Head of Commercial Operations of Aventis Pharma AG,
and/or the Chief Executive Officer of Noven, as the case may be, or their
respective designees, for discussion and resolution. If such personnel are
unable to resolve such dispute within thirty (30) days of initiating such
negotiations, the relevant Parties agree first to try in good faith to settle
the dispute by mediation in New York under the Commercial Mediation Rules of the
American Arbitration Association, before resorting to litigation.

         11.2. INDEPENDENT CONTRACTORS. In making and performing this Agreement,
the Parties are acting and shall act as independent contractors. Nothing in this
Agreement shall be deemed to create an agency, joint venture or partnership
relationship between the Parties hereto. Neither Party shall have the authority
to obligate the other Party in any respect, and neither Party shall hold itself
out as having any such authority. All personnel of Aventis, RPR, RPRIH and APPI
shall be solely employees of Aventis, RPR, RPRIH or APPI, as the case may be,
and shall not represent themselves as employees of Novartis or Noven. All
personnel of Novartis shall be solely employees of Novartis, as applicable and
shall not represent themselves as employees of Aventis, RPR, APPI, RPRIH or
Noven. All personnel of Noven shall be solely employees of Noven as applicable
and shall not represent themselves as employees of Aventis, RPR, APPI, RPRIH or
Novartis.

         11.3. ASSIGNMENT. Neither Aventis nor Novartis shall have a right to
assign this Agreement without the prior written consent of the other (which
consent shall not be unreasonably withheld or delayed); PROVIDED, HOWEVER, that

                                       16
<PAGE>   21
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

each of Aventis and Novartis may assign this Agreement to any of its Affiliates
without the prior written consent of the other; PROVIDED, FURTHER, that no such
assignment of this Agreement shall relieve the assignor of any of its
obligations or liabilities under this Agreement. Notwithstanding the foregoing,
each of Aventis and Novartis may assign this Agreement without the other's prior
written consent in connection with the transfer or sale of all or substantially
all of its assets or business or its merger or consolidation with another
Person.

         11.4. BINDING EFFECT; BENEFIT. This Agreement shall inure to the
benefit of and be binding upon the Parties hereto, and their respective
successors and permitted assigns. Nothing contained herein shall give to any
other Person, other than Noven, any benefit or any legal or equitable right,
remedy or claim.

         11.5. AMENDMENT. This Agreement may only be modified, amended or
supplemented by an instrument in writing executed by Aventis and Novartis, and,
as applicable, consented to by Noven.

         11.6. NO WAIVER. No term or provision hereof will be considered waived
by any Party, and no breach excused by any Party, unless such waiver or consent
is in writing signed on behalf of the Party against whom the waiver is asserted.
No consent by any Party to, or waiver of, a breach by any Party, whether express
or implied, will constitute a consent to, waiver of, or excuse of any other,
different or subsequent breach by any other Party.

         11.7. NOTICES. All notices, claims, certificates, requests, demands and
other communications hereunder shall be in writing and shall be delivered
personally or sent by facsimile transmission, air courier, or registered or
certified mail, return receipt requested, addressed as follows:

If to Novartis:                        If to Aventis:

Novartis Pharma AG                     Rorer Pharmaceutical Products, Inc.
Lichtstrasse 35                        3711 Kennett Pike, Suite 200
CH-4002 Basel, Switzerland             Greenville, Delaware, USA 19087
Fax:  ++41 61 324 6859                 Fax:  (302) 777-7665
Attn:  General Counsel                 Attn:  President

With copies to:                        With a copy to:

Novartis Pharma AG                     Ballard Spahr Andrews & Ingersoll, LLP
Lichtstrasse 35                        1735 Market Street, 51st Floor
CH-4002 Basel, Switzerland             Philadelphia, PA 19103
Fax:  ++41 61 324 2100                 Fax:  (215) 864-8999
Attn:  Head BD & L                     Attn:  Morris Cheston, Jr., Esq.

and

                                       17
<PAGE>   22
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

White & Case LLP
1155 Avenue of the Americas
New York, NY  10036
Fax:  (212) 354-8113
Attn:  Steven M. Betensky, Esq.

If to Noven:                            If to APPI, RPRIH or RPR:

Noven Pharmaceuticals, Inc.             c/o Aventis Pharma
11960 S.W. 144th Street                 Route 202-206, P.O. Box 6880
Miami, Florida  33186                   Bridgewater,  NJ 08807-0800
Fax:  (305) 232-1836                    Fax: (908) 231-2243
Attn: Robert C. Strauss, President,     Attn: General Counsel
      and Jeffrey F. Eisenberg, Esq.,
      General Counsel

With a copy to:                         In each case with a copy to:

Foley & Lardner                         Ballard Spahr Andrews & Ingersoll, LLP
Washington Harbour                      1735 Market Street, 51st Floor
3000 K Street, N.W.                     Philadelphia, PA 19103
Washington, D.C. 20007-5109             Fax:  (215) 864-8999
Fax: (202) 672-5399                     Attn:  Morris Cheston, Jr., Esq.
Attn:  Stephen B. Maebius, Esq.

or to such other address as the Party to whom notice is to be given may have
furnished to the other Parties in writing in accordance herewith. Any such
communication shall be deemed to have been delivered (a) when delivered, if
delivered personally, (b) when sent (with written confirmation received), if
sent by facsimile transmission on a business day, (c) on the first business day
after dispatch (with written confirmation received), if sent by facsimile
transmission on a day other than a business day, (d) on the second business day
after dispatch, if sent by air courier, and (e) on the fifth business day after
mailing, if sent by mail.

         11.8. COUNTERPARTS. This Agreement shall become binding when any one or
more counterparts hereof, individually or taken together, shall bear the
signatures of each of the Parties hereto. This Agreement may be executed in any
number of counterparts, each of which shall be deemed an original as against the
Person whose signature appears thereon, but all of which taken together shall
constitute but one and the same instrument. Each Party may execute this
Agreement on a facsimile of the Agreement. In addition, facsimile signatures of
authorized signatories of any Party shall be valid and binding and delivery of a
facsimile signature by any Party shall constitute due execution and delivery of
this Agreement.

         11.9. INTERPRETATION. The article and section headings contained in
this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement. This Agreement is the product

                                       18
<PAGE>   23

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

of negotiations between the Parties. In construing the terms hereof, no
presumption shall operate in any Party's favor as a result of its counsel's role
in drafting the terms or provisions hereof.

         11.10. GOVERNING LAW. This Agreement and any claims, disputes or causes
of action relating to or arising out of this Agreement shall be construed in
accordance with and governed by the substantive laws of the State of New York,
U.S.A. without giving effect to the conflict of laws principles thereof.

         11.11. SEVERABILITY. If any provisions of this Agreement are determined
to be invalid or unenforceable in any jurisdiction, such provisions shall be
ineffective to the extent of such invalidity or unenforceability in such
jurisdiction, without rendering invalid or unenforceable the remaining
provisions hereof or affecting the validity or enforceability of any of such
provisions of this Agreement in any other jurisdiction. The Parties will use
their best efforts to substitute the invalid or unenforceable provision with a
valid and enforceable one which conforms, as nearly as possible, with the
original intent of the Parties.

         11.12. ENTIRE AGREEMENT. This Agreement, including all exhibits and
schedules and the Related Agreements, the Existing Novartis Pharma Sublicense
Agreement and, with respect to Noven and Novartis only, the Purchaser Sublicense
Letter Agreement, embody the entire agreement and understanding between the
Parties hereto with respect to the subject matter hereof and supersede all prior
agreements, commitments, arrangements, negotiations or understandings, whether
oral or written, between the Parties hereto and their respective Affiliates with
respect thereto. There are no agreements, covenants or undertakings with respect
to the subject matter of this Agreement and the Related Agreements other than
those expressly set forth or referred to herein or in such other agreements, and
no representations or warranties of any kind or nature whatsoever, express or
implied, are made or shall be deemed to be made herein by the Parties hereto
except those expressly made in this Agreement and the Related Agreements.

         11.13. FURTHER ASSURANCES. Each Party agrees to execute, acknowledge
and deliver such further instruments, and to do all such other acts, as may be
reasonably necessary or appropriate in order to carry out the purposes and
intent of this Agreement.

         11.14. INCONSISTENCY. In the event of any inconsistency between the
terms of this Agreement and the Existing Novartis Pharma Sublicense Agreement,
the terms of this Agreement shall prevail.

                                       19
<PAGE>   24
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

         IN WITNESS WHEREOF, the Parties hereto have executed this Sublicense
Agreement as of date first above written.

                             RORER PHARMACEUTICAL PRODUCTS, INC.

                             By:        /s/ Phillip R. Ridolfi
                                 ------------------------------------------
                                      Phillip R. Ridolfi
                                      President

                             RHONE-POULENC RORER INC.

                             By:       /s/ Charles D. Dalton
                                 ------------------------------------------
                                      Charles D. Dalton
                                      Vice President

                             AVENTIS PHARMACEUTICALS PRODUCTS INC.

                             By:        /s/ Charles D. Dalton
                                 ------------------------------------------
                                      Charles D. Dalton
                                      Vice President

                             RHONE-POULENC RORER INTERNATIONAL HOLDINGS INC.

                             By:        /s/ Phillip R. Ridolfi
                                 ------------------------------------------
                                      Phillip R. Ridolfi
                                      President

                             NOVARTIS PHARMA AG

                             By:        /s/ Gerard Hazelzet
                                 ------------------------------------------
                                      Gerard Hazelzet
                                      Head Licensing Europe, Business
                                         Development and Licensing

                             By:        /s/ Gisela Schelling
                                 ------------------------------------------
                                      Gisela Schelling
                                      Legal Counsel

                                       20
<PAGE>   25
          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

Consented to with respect to the following provisions: Section 2.1 (Sublicense
to the Sublicensed Noven Intellectual Property); Section 2.2 (Assumption of
Obligations); Section 2.3 (Retention of Rights); Section 2.4 (Right to
Sublicense); Section 3.2 (Payment of Noven's Patent Costs); Sections 6.1, 6.2
and 6.5 (Infringement and Other Third Party Claims); Section 7.2(e)
(Noncompetition); Section 7.5 (Noncompetition by Noven); Article VIII
(Indemnification); Sections 9.1, 9.2, 9.3, 9.4, 9.5, 9.7, 9.8 and 9.9 (relating
generally to Term, Termination, Remedies and Penalties) and Article XI
(Miscellaneous).

NOVEN PHARMACEUTICALS, INC.

By:        /s/ Robert C. Strauss
     --------------------------------------------
         Robert C. Strauss
         President, Chief Executive Officer
         Co-Chairman

                                       21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]